GLP-1 Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 - Landscape Led by China and the U.S., Rising Partnerships, and Strong DTC-Driven Demand Push Biologics Above 65% Share
View original at globenewswire.comGLP-1 Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 - Landscape Led by China and the U.S., Rising Partnerships, and Strong DTC-Driven Demand Push Biologics Above 65% Share Dublin, Jan…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Single-agonist segment currently holds the maximum share of the GLP-1 market
80% confidenceParenteral route holds a larger share of the GLP-1 market and this trend is likely to remain the same in the coming decade
80% confidenceLifestyle changes, influence of social media, celebrity endorsements and direct to consumer advertisements have led to a surge in the demand for GLP-1 drugs
80% confidenceTri-agonist segment is likely to grow at a relatively higher CAGR
80% confidenceBiologics segment is expected to capture the majority share (over 65%) of the GLP-1 market by 2035
80% confidenceSemaglutide holds the maximum share of the GLP-1 market at present
80% confidenceLong-acting GLP-1 agonists currently dominate the market and this trend is expected to persist due to longer duration of effect compared to short-acting agonists
80% confidenceMore than 150 GLP-1 drug candidates, intended for the treatment of multiple indications, are currently either approved or being investigated by pharmaceutical companies
80% confidenceThe global GLP-1 market is estimated to grow from USD 62.2 billion in the current year to USD 157.5 billion by 2035, at a CAGR of 9.7% during the forecast period
80% confidenceThe majority of GLP-1 drug development firms are based in China (36%) and the US (28%)
80% confidenceThe efficacy of GLP-1 medications in weight management presents opportunities for wider application in non-diabetic groups, combating the worldwide obesity crisis
80% confidenceCurrently, small molecules category occupies the largest share of the GLP-1 market
80% confidenceType 2 diabetes represents a larger market share but non-alcoholic steatohepatitis segment is anticipated to experience significant market expansion in the years ahead
80% confidenceOral route of administration is likely to grow at a relatively higher CAGR
80% confidenceThe biologics sector is expected to expand at a comparatively higher CAGR due to distinct physiological characteristics such as stability, specificity, selectivity, and capacity to inhibit particular protein-protein interactions
80% confidenceClose to 50% of partnerships related to GLP-1 drugs were signed for drug development and commercialization
80% confidenceThe short-acting GLP-1 agonist segment is expected to expand at a notably higher CAGR
80% confidenceImprovements in drug administration, including implantable devices, extended-release formulations, or non-invasive methods (like transdermal patches), may enhance patient satisfaction and broaden market appeal
80% confidenceNorth America accounts for the largest share of the GLP-1 market
80% confidenceSurvodutide is likely to drive the GLP-1 market in the near future
80% confidenceOver the years, the market in Asia-Pacific is expected to grow at a higher CAGR
80% confidenceApproximately 60% of the GLP-1 drug candidates are currently being evaluated in clinical stages of development, with most targeting metabolic disorders such as Type 2 diabetes and obesity
80% confidence